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Abstract: The goal of treatment for open-angle glaucoma or ocular hypertension is to improve 
quality of life through reduction of intraocular pressure (IOP) to preserve visual function. 
Prostaglandins, as a newer class of ocular hypotensive agents, have been shown to be effec-
tive in IOP reduction by the primary mechanism of action of increase the uveoscleral outﬂ  ow. 
Bimatoprost is a member this class, but different from the other members by having an ethyl 
amide group rather than an isopropyl ester at the C-1 carbon of the alpha chain. Bimatoprost 
used once daily has been shown to be more effect in IOP reduction than other classes of topical 
ocular hypotensive agents including beta-blockers, carbonic anhydrase inhibitors, and alpha 
agonists. Comparing with other topical prostaglandins, bimatoprost may be slightly more effec-
tive in IOP reduction, but the clinical signiﬁ  cance is uncertain. The commonly reported adverse 
events associated with bimatoprost are localized to the eye and include conjunctival hyperemia, 
changes in the pigmentation of the periocular skin and iris, and eyelash darkening and growth. 
It is currently approved by the Food and Drug Administration (FDA) and the European Com-
mission (EC) for ﬁ  rst-line therapy for the reduction of elevated IOP in patients with open-angle 
glaucoma or ocular hypertension.
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Introduction
Open-angle glaucoma is estimated to affect more than 2 million individuals in the United 
States according to a meta-analysis of recent population-based studies in the United 
States, Australia, and Europe (Eye Diseases Research Prevalence Group 2004). Owing 
to the rapid aging of the US population, this number is expected to increase to more 
than 3 million by 2020 (Eye Diseases Research Prevalence Group 2004). The deﬁ  nition 
of glaucoma has changed considerably over the past several decades. The disease is no 
longer deﬁ  ned as elevated intraocular pressure (IOP) but rather a disorder consisting of 
characteristic optic nerve head and visual ﬁ  eld abnormalities (Anderson 1989). Major 
risk factors for the development of glaucomatous optic nerve damage include the level of 
IOP (Hollows and Graham 1966; David et al 1977; Sommer 1989; Sommer et al 1991), 
increasing age (Armaly et al 1980), black race (Tielsch et al 1991), positive ﬁ  nding for 
the condition in the family history (Kolker 1972), and thin central corneal thickness 
(Gordon et al 2002). However, IOP remains the only risk factor readily amenable to 
therapy. Therefore, almost all currently used strategies for the treatment of glaucoma 
are aimed at lowering or preventing a rise in IOP (Law and Caprioli in press).
The goal of glaucoma treatment is to improve quality of life through reduc-
tion of IOP to preserve visual function. In the process of IOP reduction, an ideal Clinical Ophthalmology 2007:1(3) 226
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medication should have a schedule that is simple to 
follow, be least interrupting with a patient’s life, highly 
tolerable and affordable. However, medical treatment of 
glaucoma has associated side effects, complications, and 
costs (Law and Caprioli in press). Prostaglandins (PGs), 
as a newer class of IOP-reducing agents, have gained 
tremendous popularity in management of glaucoma. This 
review is to examine the position of bimatoprost, a mem-
ber of the PGs, in glaucoma medical management.
Prostaglandins in general
Prostaglandins (PGs) are biologically active derivatives of 
arachidonic acid with diverse local responses that are tissue 
dependent. Arachidonic acid is bound to phospholipids in 
the membranes of most mammalian cells. The release of 
arachidonic acid is catalyzed by the enzyme phospholipase 
A2, and arachidonic acids are then converted into PGs by 
cyclooxygenase and PG synthetase.
PGs are the most potent ocular hypotensive agents yet 
discovered. Multiple prostanoid receptors (eg, DP, EP1 to 
EP4, FP, IP, and TP) have been identiﬁ  ed based on studies 
using molecular biologic, second-messenger, radio-ligand 
binding, and functional techniques (Coleman et al 1994). 
In particular, the FP receptor mediates little or no nocicep-
tive response, plays little or no role in regulation of vessel 
tone and capillary permeability, and is responsible for little 
or no smooth muscle contraction of the bronchioles. PGF2α 
became the PG prototype in the development of PGs for 
glaucoma treatment. In a human study of 18 nonglauco-
matous volunteers, IOP was signiﬁ  cantly reduced through 
a 24-hour period after administration of PGF2α (Giuffre 
1985). However, it was associated with a high incidence of 
adverse effects including marked conjunctival hyperemia, 
ocular irritation, foreign-body sensation, and headache. As 
a result of intense effort to modify the chemical structure of 
PGF2α to develop a compound that could reduce IOP while 
minimizing the incidence of side effects, four agents in this 
class of topical glaucoma drops are currently commercially 
available. They include latanoprost, unoprostone, travoprost, 
and bimatoprost.
The primary mechanism of action of PGs is believed 
to reduce IOP by increasing uveoscleral outﬂ  ow. This is in 
contrast to other classes of antiglaucoma medications, which 
act by increasing aqueous humor outﬂ  ow via the trabecular 
meshwork or by inhibiting aqueous production. Although 
the exact mechanisms are still not entirely clear, it appears 
that PGs facilitates the uveoscleral pathway in the ciliary 
muscle by reducing the extracellular matrix in the spaces 
between and within the ciliary muscle ﬁ  bers (Toris et al 
1997; Schachtschabel et al 2000). Activation of FP and EP2 
receptors stimulates several intracellular second messenger 
mechanisms (Lindsey et al 1994; Zhan et al 1998), which 
are thought to activate the biosynthesis of matrix metallopro-
teinases (MMPs), a family of neutral proteinases that have a 
lytic effect on extracellular matrix molecules.
Bimatoprost
Bimatoprost (Lumigan® 0.03%; Allergan, Irvine, CA, USA) 
is a synthetic PG. But unlike the prostaglandin F2α analogs 
latanoprost, travoprost, and unoprostone, bimatoprost has an 
ethyl amide rather than an isopropyl ester at the C-1 carbon 
of the alpha chain. Bimatoprost has been proposed to be 
pharmacologically similar to a newly discovered class of fatty 
acid amides otherwise known as “prostamides” (Woodward 
et al 2001, 2003). There is some evidence suggesting that 
long-term therapy with bimatoprost increases both pressure-
dependent trabecular outflow and pressure-independent 
uveoscleral outﬂ  ow via remodeling of extracellular matrix 
in the trabecular meshwork and ciliary muscle, respectively 
(Brubaker 2001; Brubaker et al 2001). It has been proposed 
that bimatoprost does not require hydrolysis to a free fatty 
acid to stimulate prostaglandin FP receptors and the pharma-
cological activities of bimatoprost are postulated to be medi-
ated by a novel receptor that is different from prostaglandin 
receptors (Woodward et al 2001). However, such a receptor 
has not yet been identiﬁ  ed. Whether bimatoprost is a pro-drug 
that is hydrolyzed to an active fatty acid for its hypotensive 
activity remains controversial. Although there are experiments 
demonstrating bimatoprost hydrolysis occurs in human ocular 
tissue, the rate of hydrolysis is either very slow or occurs in the 
presence of high concentrations of bimatoprost (Maxey et al 
2002; Davies et al 2003; Hellberg et al 2003). In a masked 
vehicle-controlled study to determine the level of bimato-
prost free acid in eyes treated with bimatoprost 0.03% before 
cataract surgery, aqueous concentrations of the free acid of 
bimatoprost were 22.0 ± 7.0 nmol and 7.0 ± 4.6 nmol at 2 
and 12 hours after the last dose of bimatoprost, respectively 
(Camras et al 2004). This concentration is about one-ﬁ  fth the 
concentration of the free acid of latanoprost in the aqueous 
humor, but the free acid of bimatoprost has been shown to be 
3–10 times more potent at the FP receptor than the free acid 
of latanoprost (Sharif et al 2002).
Efﬁ  cacy
Dose-response and dose-frequency studies in patients with 
elevated IOP have demonstrated that the most effective Clinical Ophthalmology 2007:1(3) 227
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regimen is a once-daily dosage of bimatoprost 0.03% 
(Laibovitz et al 2001). Twice-daily administration was found 
to confer no additional efﬁ  cacy and in some studies was less 
effective than once-daily administration (Brandt et al 2001; 
Laibovitz et al 2001; Sherwood et al 2003). Mean reductions 
in IOP 12 hours after administration of bimatoptost 0.03% 
ranged from 6.8 to 9.2 mmHg in randomized clinical trials, 
with reductions in IOP maintained throughout the 24-hour 
dosage interval and maintained for up to 1 year (Brandt et al 
2001; Dubiner et al 2001; Gandolﬁ   et al 2001; Laibovitz et al 
2001; Sherwood et al 2003). Bimatoprost 0.3% once-daily 
administration produced signiﬁ  cantly greater reductions in 
IOP of about 2–4 mmHg than timolol 0.5% given twice daily, 
and a signiﬁ  cantly higher percentage of patients achieved a 
target IOP of 17 mmHg with bimatoprost than with timolol 
treatment (Brandt et al 2001; Laibovitz et al 2001; Sherwood 
et al 2003). The combination of dorzolamide 2%/timolol 
0.5% was compared with bimatoprost 0.03% in a 3-month 
randomized, single-blinded trial involving 177 patients with 
ocular hypertension or glaucoma inadequately controlled with 
beta-blocker therapy. Treatment with bimatoprost 0.03% pro-
duced signiﬁ  cantly greater mean reductions in IOP at 8 AM 
than treatment with dorzolamide 2%/timolol 0.5% at every 
visit throughout the study. Furthermore, approximately twice 
as many patients had an IOP of 16 mmHg after 3 months’ 
treatment with bimatoprost than with dorzolamide/timolol 
(31% vs 14%) (Coleman et al 2003).
The clinical efﬁ  cacy of bimatoprost 0.03% has also 
been compared with other topical PGs. In a meta-analysis 
of randomized clinical trials to estimate the IOP reduction 
achieved by the most frequently prescribed glaucoma drugs, 
including latanoprost, travoprost, and bimatoprost, IOP 
was reduced from baseline by 31%–33% for the peak and 
28%–29% for the trough with topical PGs, and bimatoprost 
achieved the highest reduction of IOP at peak (van der Valk 
et al 2005). In a 6-month randomized clinical trial compar-
ing bimatoprost and latanoprost in patients with ocular 
hypertension or glaucoma, the mean change from baseline 
IOP was signiﬁ  cantly greater for bimatoprost patients than 
for latanoprost patients, the percentage of patients achiev-
ing a 20% IOP decrease was higher with bimatoprost than 
with latanoprost, and more bimatoprost patients achieved a 
lower pressure range (Noecker et al 2003). However, similar 
differences of IOP response between the two agents was 
not repeated in other studies. In a small, double-blinded, 
phase II study (n = 64) and a 3-month investigator-masked 
trial, no signiﬁ  cant difference in the IOP-lowering efﬁ  cacy 
of the drugs was observed 12 hours post-dose at the end 
of the treatment periods; however, diurnal control of IOP 
was more consistent with bimatoprost (Dubiner et al 2001; 
Gandolﬁ   et al 2001). Although the percentage of patients 
achieving a target IOP of 17 mmHg was not signiﬁ  cantly 
different between treatment groups, a signiﬁ  cantly greater 
proportion of the bimatoptost-treated patients reached a 
target IOP of 15 mmHg (29% vs 14%). In a 12-week 
comparison of the three PGs, latanoprost, bimatoprost, and 
travoprost, no statistical differences were observed between 
the three agents in mean IOP (Parrish et al 2003). The con-
ﬂ  icting ﬁ  ndings are likely due to the similarity in efﬁ  cacy 
between the three agents. In a recent published randomized, 
double-blinded, crossover comparison of bimatoprost and 
latanoprost, the 24-hour diurnal IOP is statistically lower 
with bimatoprost than latanoprost. However, the difference 
was small (0.5 mmHg) and may not be clinically meaningful 
(Konstas et al 2005). In a retrospective review of more than 
300 patients in a health management organization that had 
switched from latanoprost to bimatoprost, a statistically 
signiﬁ  cant mean IOP difference of 0.5 mmHg was observed 
favoring bimatoprost (Law et al 2005). This study also 
showed that approximately 13% of patients had a further IOP 
reduction of 3 mmHg after switching from latanoprost to 
bimatoprost compared with 5% of patients had a 3 mmHg 
reduction while using latanoprost before the switch (Figures 
1 and 2). It is likely that bimatoprost can achieve a small but 
statistically greater mean IOP reduction than latanoprost, but 
the clinical signiﬁ  cance is uncertain. In addition, individual 
responses to the different agents can be variable.
Additivity
Because of its similarity with other prostaglandin agents 
such as latanoprost and travoprost, bimatoprost is expected 
to be additive to other antiglaucoma agents with differ-
ent mechanisms of action, including β-blockers, selective 
α-agonists, carbonic anhydrase inhibitors, and parasym-
pathomimetics. However, the additivity among the three 
agents (latanoprost, travoprost, bimatoprost) is inconsistent. 
In a study with monkey eyes with laser-induced unilateral 
glaucoma, the IOP effects of the bimatoprost 0.03% or tra-
voprost 0.004% were additive to that of latanoprost 0.005%, 
with bimatoprost showing a greater additive response than 
travoprost (Gagliuso et al 2004). However, no similar ﬁ  nd-
ing was observed in human studies. A paradoxical IOP 
elevation was reported after combined therapy with latano-
prost and bimatoprost (Herndon et al 2002). In an open 
label clinical trial, bimatoprost 0.03% was combined with 
latanoprost 0.005% in one randomly assigned eye (case eye) Clinical Ophthalmology 2007:1(3) 228
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of each patient in phase 1, and in phase 2, bimatoprost was 
discontinued from the case eyes while bimatoprost was 
substituted for latanoprost in the fellow eye (control eye). 
When bimatoprost and latanoprost were used together, the 
mean IOP increased by 1.8 mmHg, and returned to previous 
values after discontinuation of bimatoprost; no mean IOP 
change was observed throughout the study in the control 
eyes (Doi et al 2005).
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Figure 1 Cumulative percentage of patients with intraocular pressure (IOP) reduction after switching from latanoprost to bimatoprost. Reproduced with permission from 
Law SK, Song J, Fang E, et al. 2005. Feasibility and efﬁ  cacy of a mass switch from latanoprost to bimatoprost in glaucoma patients in a pre-paid health maintenance organiza-
tion. Ophthalmology, 112:2123–30. Copyright © Elsevier.
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Figure 2 Cumulative percentage of patients with intraocular pressure (IOP) elevation after switching from latanoprost to bimatoprost. Reproduced with permission from 
Law SK, Song J, Fang E, et al. 2005. Feasibility and efﬁ  cacy of a mass switch from latanoprost to bimatoprost in glaucoma patients in a pre-paid health maintenance organiza-
tion. Ophthalmology, 112:2123–30. Copyright © Elsevier.Clinical Ophthalmology 2007:1(3) 229
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Systemic adverse reactions
Systemic adverse events reported after treatment with 
bimatoprost 0.03% have included colds and upper respiratory 
tract infections occurring in approximately 10% of patients, 
and headaches, abnormal liver function tests, asthenia, and 
hirsutism. Bimatoprost 0.03% did not have any clinically 
signiﬁ  cant effect on heart rate or blood pressure in patients 
with glaucoma or ocular hypertension in clinical trials (Brandt 
et al 2001; Dubiner et al 2001; Laibovitz et al 2001).
Since bimatoprost is similar in structure and effects with 
the other topical PGs, it is important to be aware of the side 
effects reported with the other PGs. There is a case report 
of abdomincal cramps associated with travoprost conﬁ  rmed 
by dechallenge and rechallenge procedures (Lee 2005). 
Other systemic events, each with an incidence of 1% or 
2%, included chest pain/angina, muscle/joint/back pain, and 
rash/allergic skin reaction. Angina (Mitra et al 2001), arterial 
hypertension (Peak and Sutton 1998), and tachycardia have 
been anecdotally reported following latanoprost use. In a 
randomized study, headache was more frequent in patients 
receiving latanoprost than in those receiving bimatoprost, 
although this difference did not reach statistical signiﬁ  -
cance (Gandolﬁ   et al 2001). Patients with no prior history 
of migraine and/or headache have reported migraine after 
receiving latanoprost treatment (Weston 2001).
Bimatoprost is classiﬁ  ed as category C according to 
the use-in-pregnancy ratings of the US Food and Drug 
Administration (FDA). Experience of bimatoprost use during 
pregnancy is limited. However, in an observation study of 
10 pregnant women exposed to latanoprost during the ﬁ  rst tri-
mester, 9 women delivered normal fetuses with no malforma-
tions. One pregnancy was complicated by miscarriage, which 
occurred 2 weeks after treatment was ended in a 46-year-old 
woman, primi-gravida, who had increased reproductive risk 
related to her advanced age (De Santis et al 2004).
Local adverse reactions
The most common adverse event associated with bimato-
prost 0.03% treatment was conjunctival hyperemia, which 
occurred in 42%–46% of patients (Brandt et al 2001; Gandolﬁ   
et al 2001; Sherwood et al 2001). Approximately 1%–4% 
of patients discontinued treatment with bimatoprost 0.03% 
because of conjunctival hyperemia (Brandt et al 2001; 
Sherwood et al 2001). Bimatoprost 0.03% has been reported 
to cause changes in the pigmentation of tissues, including 
pigmentation of the periocular skin and iris, and eyelash 
darkening. Eyelash growth has also been reported in 12.6% 
to 35.7% of patients during clinical trials of bimatoprost 
0.03% (Brandt et al 2001; Gandolﬁ   et al 2001; Sherwood 
et al 2001). Significantly more conjunctival hyperemia 
and increased eyelash growth were reported with bimato-
prost than with latanoporst, whereas headache was more 
frequently seen in latanoprost than bimatoprost recipients 
(Gandolﬁ   et al 2001; Noecker et al 2003; Parrish et al 2003; 
Stewart et al 2003). Cystoid macular edema in patients at 
high risk can occur when treated with bimatoprost. There is 
a case report of cystoid macular edema, which developed in 
a patient switched from latanoprost to bimatoprost 9 months 
after cataract surgery (Carrillo et al 2004).
Anterior uveitis has also been observed in approximately 
1% of patients receiving latanoprost which resolves with 
corticosteroid therapy (Smith et al 1999). Association of 
latanoprost and uveitis has been conﬁ  rmed with a dechallenge 
and rechallenge method in two studies (Fechter et al 1998; 
Warwar et al 1998). Use of other PGs, including bimato-
prost should be cautioned in patients with known tendency 
of ocular inﬂ  ammatory reaction. In fact, administration of 
latanoprost to patients with active uveitis at the time of treat-
ment does not appear to lower IOP (Smith et al 1999; Sacca 
et al 2001).The association of PGs and ocular infection of 
herpes simplex virus has been documented with latanoprost. 
Latanoprost has been shown to worsen acute herpetic keratitis 
in the rabbit eye (New Zealand white (NZW) rabbit) and 
increase the risk of recurrences in latently infected animals 
(Kaufman et al 1999). However, in the Induced Reactiva-
tion and Spontaneous Shedding HSV-1/NZW rabbit latency 
models, latanoprost was not found to promote ocular shed-
ding of HSV-1 (Gordon et al 2003). There are case reports 
that herpes simplex keratitis developed after initiation of 
latanoprost therapy with dechallenge and rechallenge method 
(Wand et al 1999). In one case report, 2 patients developed 
HSV dermatitis of the periocular skin after using latanoprost 
(Morales et al 2001). Use of any topical PGs in patients with 
history of ocular herpetic infection may better be avoided.
Indications
Bimatoprost is effective in reduction of elevated IOP in 
patients with open-angle glaucoma or ocular hypertension. It 
is similar in efﬁ  cacy and safety proﬁ  les to another older PG, 
latanoprost, which has gained wider experience and demon-
strated effectiveness in several glaucoma subtypes, including 
chronic angle closure glaucoma (Aung et al 2000; Hung et al 
2000; Chew et al 2004; Sihota et al 2004; Kook et al 2005), 
pigmentary glaucoma (Mastropasqua et al 1999), pseudo-
exfoliation glaucoma (Konstas et al 2003, 2004), and low 
tension glaucoma (Rulo et al 1996; McKibbin et al 1999; Clinical Ophthalmology 2007:1(3) 230
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Ang et al 2004). Because of its similarity with latanoprost, 
bimatoprost is expected to be effective in IOP reduction 
in these glaucoma subtypes. However, its effectiveness in 
IOP reduction in glaucoma associated with uveitis or neo-
vascularization is probably questionable in addition to the 
possibility of aggravation of inﬂ  ammation. Although PGs 
are shown to be effective in IOP reduction for chronic angle 
closure glaucoma, its effectiveness is unreliable if a quick 
reduction of IOP is desirable such as in acute angle closure 
attack, because of its relatively slow onset of action.
Position of bimatoprost 
in the management of glaucoma
Therapeutic use of topical PGs in management of glaucoma 
has grown rapidly over the past decade, and it now surpasses 
nonselective β-blockers as the ﬁ  rst choice of glaucoma medi-
cal therapy due to the excellent efﬁ  cacy and systemic safety 
proﬁ  les as well as improved compliance with once-a-day 
usage. Bimatoprost is currently approved by the FDA and the 
EC for ﬁ  rst-line therapy for the reduction of elevated IOP in 
patients with open-angle glaucoma or ocular hypertension.
There is subtle yet important distinction between the 
concepts of ﬁ  rst-line versus ﬁ  rst-choice medical therapy. 
Topouzis clariﬁ  ed that ﬁ  rst-line treatment could be deﬁ  ned 
as a treatment that has been approved by an ofﬁ  cial regula-
tory body as an initial therapy to control IOP, whereas a 
ﬁ  rst-choice treatment is one that a physician prefers to use 
as an initial IOP-lowering therapy (Topouzis 2006). In the 
healthcare system of certain countries, a designation of 
ﬁ  rst-line therapy may be a result of nonmedical decisions 
including the cost of medication. While ﬁ  rst choice therapy 
is the result of the physician’s medical judgment based on 
experience and medical evidence and the patient’s decision 
(Topouzis 2006). The inﬂ  uence of ﬁ  rst-line concept on 
ﬁ  rst-choice of medical therapy often cannot be ignored. In 
an ophthalmic practice environment that physicians have 
the freedom to choose the best topical glaucoma therapy 
possible for their patients, the factors of ﬁ  rst-choice consid-
eration include the ability of the drug to lower IOP, contra-
indication and adverse effects, and treatment convenience 
and cost. Based on these criteria for evaluation, bimatoprost 
is highly effective for IOP reduction, has excellent systemic 
safety proﬁ  les, and is easy to use with once-daily schedule. 
In terms of local adverse proﬁ  le, it is associated with a higher 
rate of conjunctival hyperemia, pigmentation of the peri-
ocular skin and iris, and eyelash darkening compared with 
other PGs. However, in a study of assessing the feasibility 
of an automatic switch of a large number of patients from 
latanoprost to bimatoprost in a prepaid health maintenance 
organization, a large majority of patients (87% based on 
computerized ophthalmic medication dispensing record, and 
89.3% based on clinical data of one clinical facility) stay 
with bimatoprost after the switch (Law et al 2005). Being a 
newer class of antiglaucoma medications without available 
generic substitutes, brimatoprost is generally more expen-
sive than other classes of antiglaucoma medications.
Decision of ﬁ  rst-choice medical therapy should be based 
on an individualized approach. A good choice of medication 
does not necessarily equate to appropriate use of medica-
tion. Some general principles of medication use apply to 
bimatoprost as well. It is well recognized that responses to 
medical therapy vary among individual patients. Therefore, 
enough time should be allowed for the clinician to determine 
whether the patient has responded to the medications or not. 
Once the patient has started a new medicine, he should be 
monitored for adverse reactions. Commonly, some patients 
will experience mild side effects, such as ocular irritation or 
blurred vision, when ﬁ  rst using a topical medication. Thus, a 
useful follow-up time interval is about 2–4 weeks to deter-
mine the clinical effectiveness of therapy and the patient’s 
ability to tolerate the medication. Lack of compliance to 
medical therapy is a major hurdle for glaucoma control. 
In the follow-up evaluations, the patient’s compliance, the 
correct method of instillation of the drops, the proper stor-
age of medications, and the appropriate treatment schedule 
should be reviewed with the patient and family or caregiver, 
if present (Law and Coleman 2000). Overall, a proactive 
approach taken by the prescribing physician may translate 
into a long-lasting patient–physician relationship and better 
treatment outcome.
Summary
In summary, the goal of treating patients with glaucoma is to 
minimize any adverse impact of the disease and treatment on 
the patient’s life. Bimatoprost, based on the efﬁ  cacy, safety 
and ease of use, has been approved as a ﬁ  rst-line treatment 
for glaucoma, and well positioned among the ﬁ  rst-choices 
in glaucoma medical therapy.
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